Cybin Continues Advancement of Psilocybin Program in Major Depressive Disorder

PRISM Emerging Psychedelics Index company, Cybin, Inc (NYSE American: CYBN) has been granted an important patent in support of the company’s proprietary deuterated psilocybin analog program in Major Depressive Disorder (MDD). CYB003 is a new chemical entity (NCE) and has been granted FDA Breakthrough Therapy Designation for the adjunctive treatment of MDD. Cybin has successfully completed a Phase 2 trial of CYB003 in participants with moderate to severe MDD.

Doug Drysdale, Chief Executive Officer of Cybin, commented on the company’s program for MDD, saying, “As we continue to advance CYB003, our deuterated psilocybin analog program for the adjunctive treatment of MDD, further protecting our intellectual property through patent protection is an important achievement. The strength of our patents supporting CYB003 underscore our commitment to developing innovative, next-generation, commercially scalable therapeutics to address the significant unmet medical need in MDD.”

Cybin expects to commence enrollment for a multinational, multisite Phase 3 program evaluating CYB003 in MDD around mid-year 2024.

“With our robust patent portfolio, and the recent Breakthrough Therapy Designation by the U.S. Food and Drug Administration, we are encouraged by our regulatory pathway for CYB003 and are positioned to move quickly to progress the program,” said Mr. Drysdale.

This week, Cybin also announced the publication of its research on phenethylamine serotonin 5-HT2 receptor agonists in the Journal of Medicinal Chemistry, a prestigious bi-weekly peer-reviewed publication.

Cybin’s patent portfolio now includes more than 50 granted patents and over 170 pending applications. U.S. patent 11,958,807 is expected to provide exclusivity until 2041.

About Cybin

Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions.

Cybin’s goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens. The Company is currently developing CYB003, a proprietary deuterated psilocybin analog for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For company updates and to learn more about Cybin, visit www.cybin.com or follow the team on X, LinkedIn, YouTube and Instagram.